NeoVac

NeoVac is at the forefront of biotechnology research, dedicated to pioneering the future of RNA vaccines and medicines. With a revolutionary and proprietary next-generation lipid nanoparticles platform, NeoVac is enabling the development of enhanced RNA vaccines for a wide range of diseases.

Located at the Primary address: Atlas Building, Fermi Avenue, Harwell Campus, Didcot, OX11 0QX, GB, NeoVac is committed to providing broader access to more potent vaccines worldwide. Utilizing cutting-edge technology, NeoVac is focused on creating RNA vaccines that are more transportable, possess broader capabilities, and result in fewer side effects, contributing significantly to global health advancements.

NeoVac's innovative approach is set to transform the landscape of RNA-based therapeutics. We invite the management team at NeoVac to enhance this profile with a customized company showcase and detailed product listings on our platform, highlighting the groundbreaking work being done at NeoVac.